The week in pharma: action, reaction and insight – week to July 29

31 July 2022

By Barbara Obstoj-Cardwell. Managing editor

Regulatory events featured in last week’s news, first with US biotech major Biogen announcing that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for tofersen, a potential treatment for amyotrophic latera sclerosis (ALS), for priority review. Also, Swiss women’s health specialist ObsEva suffered a setback, as the FDA said it is seeking additional data on its NDA for linzagolix for uterine fibroids. On the M&A front, Dutch firm NewAmsterdam Pharma last week announced a merger with special purpose acquisition company (SPAC) Frazier Lifesciences. There was good news for US mRNA specialist Moderna on Friday, when it announced receiving a new contract from the US government for its COVID-19 booster jab, mRNA-1273.222, worth $1.74 billion.

Move over Aduhelm, it’s tofersen’s turn

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK